The Relationship Between Glasgow Prognostic Score and Hospital Duration in Patients with Inflammatory Bowel Diseases

Overview

Journal Asia Pac J Clin Nutr

Specialty Nutritional Sciences

Date 2024 Jul 5

PMID 38965723

Authors

Tao Tan

Anqi Song

Molian Tang

Jialu Wang

Yi Feng

Renying Xu

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Both hypoalbuminemia and inflammation were common in patients with inflammatory bowel diseases (IBD), however, the combination of the two parameters on hospital duration re-mained unknown.

Methods And Study Design: This is a retrospective two-centre study performed in two tertiary hospitals in Shanghai, China. Serum levels of C-Reactive Protein (CRP) and albumin (ALB) were measured within 2 days of admission. Glasgow prognostic score (GPS), based on CRP and ALB, was calculated as follows: point "0" as CRP <10 mg/L and ALB ≥35 g/L; point "1" as either CRP ≥10 mg/L or ALB <35 g/L; point "2" as CRP ≥10 mg/L and ALB <35 g/L. Patients with point "0" were classified as low-risk while point "2" as high-risk. Length of hospital stay (LOS) was defined as the interval between admission and discharge.

Results: The proportion of low-risk and high-risk was 69.3% and 10.5% respectively among 3,009 patients (65% men). GPS was associated with LOS [β=6.2 d; 95% CI (confidence interval): 4.0 d, 8.4 d] after adjustment of potential co-variates. Each point of GPS was associated with 2.9 days (95% CI: 1.9 d, 3.9 d; ptrend<0.001) longer in fully adjusted model. The association was stronger in patients with low prealbumin levels, hypocalcaemia, and hypokalaemia relative to their counterparts.

Conclusions: GPS was associated with LOS in IBD patients. Our results highlighted that GPS could serve as a convenient prognostic tool associated with nutritional status and clinical outcome.

References

Bischoff S, Bager P, Escher J, Forbes A, Hebuterne X, Lodberg Hvas C . ESPEN guideline on Clinical Nutrition in inflammatory bowel disease. Clin Nutr. 2023; 42(3):352-379. DOI: 10.1016/j.clnu.2022.12.004. View

Liu J, Ge X, Ouyang C, Wang D, Zhang X, Liang J . Prevalence of Malnutrition, Its Risk Factors, and the Use of Nutrition Support in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2022; 28(Suppl 2):S59-S66. PMC: 10686604. DOI: 10.1093/ibd/izab345. View

Miao J, Quan X, Zhang C, Zhu H, Ye M, Shen L . Comparison of two malnutrition risk screening tools with nutritional biochemical parameters, BMI and length of stay in Chinese geriatric inpatients: a multicenter, cross-sectional study. BMJ Open. 2019; 9(2):e022993. PMC: 6411257. DOI: 10.1136/bmjopen-2018-022993. View

Cooper M, Gittoes N . Diagnosis and management of hypocalcaemia. BMJ. 2008; 336(7656):1298-302. PMC: 2413335. DOI: 10.1136/bmj.39582.589433.BE. View

Jansson H, Cornillet M, Bjorkstrom N, Sturesson C, Sparrelid E . Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort. Eur J Surg Oncol. 2019; 46(5):804-810. DOI: 10.1016/j.ejso.2019.12.008. View

Unwin R, Luft F, Shirley D . Pathophysiology and management of hypokalemia: a clinical perspective. Nat Rev Nephrol. 2011; 7(2):75-84. DOI: 10.1038/nrneph.2010.175. View

Gremese E, Bruno D, Varriano V, Perniola S, Petricca L, Ferraccioli G . Serum Albumin Levels: A Biomarker to Be Repurposed in Different Disease Settings in Clinical Practice. J Clin Med. 2023; 12(18). PMC: 10532125. DOI: 10.3390/jcm12186017. View

Devakonda A, George L, Raoof S, Esan A, Saleh A, Bernstein L . Transthyretin as a marker to predict outcome in critically ill patients. Clin Biochem. 2008; 41(14-15):1126-30. DOI: 10.1016/j.clinbiochem.2008.06.016. View

Bruzzese V, Zullo A, Picchianti Diamanti A, Ridola L, Lorenzetti R, Marrese C . Vitamin D deficiency in patients with either rheumatic diseases or inflammatory bowel diseases on biologic therapy. Intern Emerg Med. 2016; 11(6):803-7. DOI: 10.1007/s11739-016-1415-9. View

10.

Sandhu A, Mosli M, Yan B, Wu T, Gregor J, Chande N . Self-Screening for Malnutrition Risk in Outpatient Inflammatory Bowel Disease Patients Using the Malnutrition Universal Screening Tool (MUST). JPEN J Parenter Enteral Nutr. 2015; 40(4):507-10. DOI: 10.1177/0148607114566656. View

11.

Keetarut K, Zacharopoulou-Otapasidou S, Bloom S, Majumdar A, Patel P . An evaluation of the feasibility and validity of a patient-administered malnutrition universal screening tool ('MUST') compared to healthcare professional screening in an inflammatory bowel disease (IBD) outpatient clinic. J Hum Nutr Diet. 2017; 30(6):737-745. DOI: 10.1111/jhn.12481. View

12.

Forrest L, McMillan D, McArdle C, Angerson W, Dunlop D . Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003; 89(6):1028-30. PMC: 2376960. DOI: 10.1038/sj.bjc.6601242. View

13.

Argeny S, Stift A, Bergmann M, Mittlbock M, Maschke S, Riss S . The modified Glasgow prognostic score in Crohn's disease-does it predict short-term outcome?. Eur Surg. 2019; 50(4):177-182. PMC: 6724747. DOI: 10.1007/s10353-018-0518-0. View

14.

Mosli M, Zou G, Garg S, Feagan S, MacDonald J, Chande N . C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015; 110(6):802-19. DOI: 10.1038/ajg.2015.120. View

15.

Beck F, Rosenthal T . Prealbumin: a marker for nutritional evaluation. Am Fam Physician. 2002; 65(8):1575-8. View

16.

Yamamoto-Furusho J, Bosques-Padilla F, de-Paula J, Galiano M, Ibanez P, Juliao F . Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. Rev Gastroenterol Mex. 2016; 82(1):46-84. DOI: 10.1016/j.rgmx.2016.07.003. View

17.

Wang Y, Li P, Li J, Lai Y, Zhou K, Wang X . The prognostic value of pretreatment Glasgow Prognostic Score in patients with esophageal cancer: a meta-analysis. Cancer Manag Res. 2019; 11:8181-8190. PMC: 6732518. DOI: 10.2147/CMAR.S203425. View

18.

Massironi S, Vigano C, Palermo A, Pirola L, Mulinacci G, Allocca M . Inflammation and malnutrition in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2023; 8(6):579-590. DOI: 10.1016/S2468-1253(23)00011-0. View

19.

Chen J, Liu T, Gao S, Tong X, Deng F, Nie B . Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China. World J Gastroenterol. 2018; 23(46):8235-8247. PMC: 5739930. DOI: 10.3748/wjg.v23.i46.8235. View

20.

Park J, Cheon J . Incidence and Prevalence of Inflammatory Bowel Disease across Asia. Yonsei Med J. 2021; 62(2):99-108. PMC: 7859683. DOI: 10.3349/ymj.2021.62.2.99. View